Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Hansjoerg Toll"'
Autor:
William C. Lamanna, Robert Ernst Mayer, Alfred Rupprechter, Michael Fuchs, Fabian Higel, Cornelius Fritsch, Cornelia Vogelsang, Andreas Seidl, Hansjoerg Toll, Martin Schiestl, Johann Holzmann
Publikováno v:
Scientific Reports, Vol 7, Iss 1, Pp 1-8 (2017)
Abstract Etanercept is a TNFα receptor Fc fusion protein used for the treatment of rheumatic disease and psoriasis. Physicochemical and functional investigation of process fractions during development of the etanercept biosimilar GP2015 (Erelzi®) r
Externí odkaz:
https://doaj.org/article/c7209dcd6ffd42fea8b0b256f819198c
Autor:
William C. Lamanna, Andreas Seidl, Johann Holzmann, Hansjoerg Toll, Martin Hartinger, Anna Hausberger
Publikováno v:
BioDrugs. 30:233-242
Filgrastim is a recombinant, non-glycosylated form of human granulocyte colony-stimulating factor, used to stimulate leukocyte proliferation in patients suffering from neutropenia. Since the expiration of patents associated with Amgen’s filgrastim
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cc668c8fd721c131439855f41d2420b0
https://doi.org/10.1007/s40259-016-0169-2
https://doi.org/10.1007/s40259-016-0169-2
Autor:
Fabian Higel, Andreas Seidl, Michael Fuchs, William C. Lamanna, Alfred Rupprechter, Robert Ernst Mayer, Hansjoerg Toll, Johann Holzmann, Cornelia Vogelsang, Cornelius Fritsch, Martin Schiestl
Publikováno v:
Scientific Reports
Scientific Reports, Vol 7, Iss 1, Pp 1-8 (2017)
Scientific Reports, Vol 7, Iss 1, Pp 1-8 (2017)
Etanercept is a TNFα receptor Fc fusion protein used for the treatment of rheumatic disease and psoriasis. Physicochemical and functional investigation of process fractions during development of the etanercept biosimilar GP2015 (Erelzi®) revealed a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::845029578a6b90a60d71bff770337362
https://pubmed.ncbi.nlm.nih.gov/28638112
https://pubmed.ncbi.nlm.nih.gov/28638112
Publikováno v:
Analytical Biochemistry. 463:1-6
Host cell proteins (HCPs) are process-related impurities present in biopharmaceuticals and are generally considered to be critical quality attributes. Changes in a biopharmaceutical production process may result in qualitative shifts in the HCP popul
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::264c9cf2ada216e3e820094dd0550f5e
https://doi.org/10.1016/j.ab.2014.06.005
https://doi.org/10.1016/j.ab.2014.06.005
Publikováno v:
Analytical and Bioanalytical Chemistry
Protein therapeutics have emerged as a major new class of pharmaceuticals. One important shelf-life-limiting factor of biopharmaceuticals is methionine oxidation, and therefore, it is important that analytical methods are able to thoroughly character
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2be6118488f00b5d3c358537b7d72f04
https://doi.org/10.1007/s00216-013-7138-0
https://doi.org/10.1007/s00216-013-7138-0